OR WAIT null SECS
March 18, 2025
Article
The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.
March 12, 2025
Video
In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.
In this video, part 4 of a 5-part series, panelists discuss gaps in clinician education regarding food allergies and anaphylaxis.
In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.
March 10, 2025
Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.
At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.
March 07, 2025
HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.
March 06, 2025
This February 2025 month in review covers key updates in allergy, including advancements in immunotherapy and new insights on food allergy desensitization.
March 03, 2025
A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.
Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.
